Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck. -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (238)	12/10/1999 1:48:00 AM
From: RWReeves	Read Replies (2) \| Respond to of 743

Somebody was asking about therapies for failed Rit patients. Although it was in today or yesterday's BW the DJ article on IMMU is not specific on this point. Check out BW for 12/7 or 12/8. Anyway, looks interesting; Small Wonders kicked out of IMMU at about 3 1/2 'cause we didn't like the pump action down at 1- 1/2 that went on for the past year. I may have been wrooo, reeeee, wrow.. uh sold too soon. RWR NEW ORLEANS (Dow Jones)--Immunomedics Inc. (IMMU, news, msgs) said a study of the radioactive version of its Epratuzumab therapy for non-Hodgkin's lymphoma yielded promising initial results. In a press release Tuesday, the company said in the study of non-Hodgkin's lymphoma patients who had failed high-dose chemotherapy and antibody therapy (BW named it as Rituximab-RWR), half the subjects showed objective responses when treated with the monoclonal antibody labeled with a potent radioscope (Hey DJ, what's a radioscope?). Objective responses are complete or partial remissions. Not bad, remember these are failed chemo and rit patients. The biopharmaceutical company said although it had not yet reached the optimal therapy dose, the study, conducted by the Garden State Cancer Center, St. Joseph's Hospital and the University of Pennsylvania Hospital, provided good evidence of tumor response. In addition, the company said no immune reaction to the product was observed. As reported Monday, a separate study of the non-radioactive version of Epratuzumab reported objective responses in almost 70% of patients with indolent non-Hodgkin's lymphomas at the optimal doses given once weekly over four weeks. There's that Hot/Cold again. Immunomedics shares recently traded at 3 13/16, down 1/8 or 3.2%, on Nasdaq volume of 1.18 million shares. Average volume is 332,116 shares. -Cressida Connolly; Dow Jones Newswires; 201-938-5400